Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Molindone - Supernus Pharmaceuticals

Next Previous
Drug Profile

Molindone - Supernus Pharmaceuticals

Alternative Names: AFX 2201; EN-1733A; Molindone hydrochloride; Molindone XR; SPN-810; SPN-810M; Zalvari

Latest Information Update: 29 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Afecta Pharmaceuticals
  • Developer Supernus Pharmaceuticals
  • Class Antipsychotics; Behavioural disorder therapies; Indoles; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Attention-deficit hyperactivity disorder

Most Recent Events

  • 16 May 2024 Supernus Pharmaceuticals terminates the phase III extension CHIME 4 trial in Attention deficit hyperactivity disorder (In children, In adolescents, Adjunctive treatment) in USA due to lack of efficacy (NCT02691182)
  • 11 Apr 2023 Supernus in licensed Molidone from Afecta Pharmaceuticals before April 2023 (Afecta Pharmaceuticals, April 2023)
  • 22 Oct 2020 Supernus Pharmaceuticals terminates a phase III trial in Attention deficit hyperactivity disorder in USA (NCT03597503)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top